Merdad Parsey

Director at Sagimet Biosciences

Dr. Parsey joined Sagimet Biosciences (then 3-V) as its President and Chief Executive Officer in September 2010. Prior to joining the Company, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas. Prior to Dr. Parsey’s tenure with Genentech, he was with Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in respiratory, inflammation, virology, neurology, ophthalmology and gastrointestinal diseases. In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine. He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Timeline

  • Director

    Current role